

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No securities may be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the company making the offer, its management, as well as financial statements. No public offer of securities is to be made by the Issuer in the United States.*



**Yestar Healthcare Holdings Company Limited**

**巨星醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2393)**

**NOTICE OF RESULTS OF THE SCHEME MEETING  
IN THE GRAND COURT OF THE CAYMAN ISLANDS**

**FINANCIAL SERVICES DIVISION**

**CAUSE NO. FSD 0391 OF 2023 (JAJ)**

**IN THE MATTER OF SECTION 86 OF THE COMPANIES ACT  
(2023 REVISION)**

**AND**

**IN THE MATTER OF YESTAR HEALTHCARE HOLDINGS COMPANY  
LIMITED (巨星醫療控股有限公司)**

**AND**

**APPOINTMENT OF SUCCESSOR RSA AGENT**

This announcement is made by Yestar Healthcare Holdings Company Limited (巨星醫療控股有限公司) (the “**Company**”) pursuant to Rules 13.09(2) and 37.47(B) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Unless otherwise defined herein, terms used in this Notice have the same meanings as defined in the explanatory statement originally dated 22 January 2024 and subsequently amended on 8 February 2024 relating to the proposed scheme of arrangement between the Company and the Scheme Creditors (as defined therein) under section 86 of the Cayman Islands Companies Act (2023 Revision) (the “**Scheme**”).

Reference is made to a notice of Scheme Meeting dated 22 January 2024 issued by the Company to the Scheme Creditors to convene a meeting of Scheme Creditors (the “**Scheme Meeting**”) for the purposes of considering and, if thought fit, approving the Scheme (with or without modification, addition or condition approved or imposed by the Court). Reference is also made to the announcement of the Company dated 8 February 2024 relating to the resignation of Madison Pacific Trust Limited as RSA Agent and the proposed appointment of Serica Agency Limited as successor RSA Agent.

## **RESULTS OF THE SCHEME MEETING**

The Company is pleased to announce that at the Scheme Meeting convened and held at the office of Dechert at 31/F Jardine House, One Connaught Place, Central, Hong Kong, which commenced at 8:02 p.m. Hong Kong time on 19 February 2024, the equivalent time being 7:02 a.m. Cayman Islands time on 19 February 2024, a total of 124 Scheme Creditors holding Voting Claims in the aggregate amount of US\$202,362,237 participated in the Scheme Meeting with 124 Scheme Creditors holding Voting Claims in the aggregate amount of US\$202,362,237 voting in favour of the Scheme (being a majority in number of the Scheme Creditors attending and voting at the Scheme Meeting either in person or by proxy and representing 100% of the total value of the Scheme Creditors attending and voting). As such, the Scheme has been approved by the requisite majorities of the Scheme Creditors. The Scheme will be subject to subsequent approval and sanction of the Court.

The Company wishes to announce that it will seek the sanction of the Scheme by the Court at a hearing listed to take place at 10:00 a.m. Cayman Islands time on 28 February 2024, the equivalent being 11:00 p.m. Hong Kong time on 28 February 2024 (the “**Scheme Sanction Hearing**”). Any Scheme Creditor is entitled (but not obliged) to attend the Scheme Sanction Hearing, through legal counsel, to support or oppose the sanction of the Scheme and should notify the Company and its advisors in advance if it intends to do so.

For further information, please contact the Information Agent or the Company, in each case, using the contact details below:

Scheme Creditors (who are not Blocked Scheme Creditors) may contact:

**Morrow Sodali Limited**

**Address:**

In Hong Kong: 29/F, No. 28 Stanley Street, Central, Hong Kong  
In London: 103 Wigmore Street, W1U 1QS, London, United Kingdom

Phone: Hong Kong: +852 2319 4130/London: +44 20 4513 6933

Transaction Website (document posting website):

<https://projects.morrowsodali.com/yestar>

Scheme AHL Portal (for submission of the Account Holder Letter):

<https://portal.morrowsodali.com/yestarAHL>

Email: [yestar@investor.morrowsodali.com](mailto:yestar@investor.morrowsodali.com)

Blocked Scheme Creditors may contact:

**Yestar Healthcare Holdings Company Limited**

Address: Suite 2105, 21/F Central Plaza, 18 Harbour Road, Hong Kong

Phone: +852 34228938

Email: [bond@yesstarnet.com.cn](mailto:bond@yesstarnet.com.cn)

**APPOINTMENT OF SUCCESSOR RSA AGENT**

The Company also wishes to inform the Scheme Creditors that Serica Agency Limited has been appointed as RSA Agent with effect from 14 February 2024.

**Shareholders, Noteholders and potential investors should note that the successful implementation of the proposed Restructuring is still subject to certain legal procedures under Cayman laws, including the Scheme being sanctioned by the Court as well as the satisfaction or waiver of any condition precedents in respect of the Scheme. Shareholders, Noteholders and potential investors are advised to exercise caution when dealing in the securities of the Company or the Notes.**

By order of the Board

**Yestar Healthcare Holdings Company Limited**

**Liao Changxiang**

*CEO and Executive Director*

20 February 2024

*As at the date of this announcement, the executive Directors are Ms. Liao Changxiang, Ms. Wang Hong and Mr. Liang Junxiong; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Mr. Zeng Jinsong, Mr. Zhao Ziwei and Mr. Koeswondo Michael David.*